KeyBanc reiterates Lonza stock rating on strong modality positioning By Investing.com

FierceBiotechASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout

FierceBiotechASCO: Revolution Medicines confident in RAS leadership as rivals square up

FierceBiotechASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

Endpoints News#ASCO26: Yes, Revolution Medicines' pancreatic cancer data are that good

Endpoints News#ASCO26: Summit, Akeso drug reduces death by 34% in China lung cancer study

BioPharma DiveAkeso, Summit drug extends survival in closely watched lung cancer trial

BioPharma Dive‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancer

Science Daily BiotechThe ocean's health may depend on a tiny microbe inside fish

Thermo FisherIs Thermo Fisher (TMO) Turning AI-Enabled Orbitraps Into a Durable Edge in Life Sciences Tools? - simplywall.st

Endpoints News#ASCO26: Personalized cancer vaccines may help brain cancer patients live longer

Endpoints News#ASCO26: Grail’s cancer blood test isn’t ready for widespread use, experts say

FierceBiotechIn next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approach